Novartis’ Pluvicto presents survival benefit for castration-resistant prostate cancer
pharmaphorum
DECEMBER 5, 2022
A vast majority of patients diagnosed with CRPC already present with metastases at the time of diagnosis. The findings will be presented at an upcoming medical meeting and submitted to the FDA for regulatory approval in 2023. Prostate cancer is the most frequently diagnosed cancer in men in 112 countries.
Let's personalize your content